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Abstract
Background:  This study evaluated the frequency of cognitive impairment in patients with
Fibromyalgia syndrome (FMS) using the Mini Mental State Examination (MMSE).
Methods: We analyzed baseline data from all 46 patients with FMS and 92 age- and sex-matched
controls per diagnosis of neuropathic (NeP) or mixed pain (MP) selected from a larger prospective
study.
Results: FMS had a slight but statistically significant lower score in the adjusted MMSE score (26.9;
95% CI 26.7-27.1) than either NeP (27.3; 95% CI 27.2-27.4) or MP (27.3; 27.2-27.5). The
percentage of patients with congnitive impairment (adjusted MMSE ≤ 26) was numerically higher in
FMS (15%; 95% CI 6.3-29) compared with NeP (5%; 95% CI 1.8-12.2) or MP (5%; 95% CI 1.8-12.2)
and higher than in the same age stratum of the general population (0.05%).
Conclusions: Compared with the population reference value, patients with FMS showed high
frequency of cognitive impairment.
Background
Fibromyalgia syndrome (FMS) is a common chronic mus-
culoskeletal disorder characterized by the presence of
widespread pain and multiple tender points on physical
examination [1]. Other important accompanying symp-
toms of FMS are fatigue, sleep disturbance, psychological
distress and cognitive disturbance [1]. In 1990, the Amer-
ican College of Rheumatology (ACR) published diagnos-
tic criteria for FMS -namely, widespread pain (both sides
of the body, above and below the waist, and in the cervical
spine, anterior chest, thoracic spine or low back), and
pain upon digital palpation in at least 11 of 18 specified
tender point sites [2], although it was not officially recog-
nized as an illness by the World Health Organization until
1992. [3]
FMS is a widespread disorder of unknown etiology that
affects an estimated 1-4% of the general population. [4] It
may occurs in 2.1 -5.7% of the general adult population,
making up 10 -20% of rheumatologic consultations and 5
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-8% of primary care consultations, being the most fre-
quent cause of general and chronic skeletal muscular pain.
[5-7] Women are about nine times more likely to develop
FMS than men. [4,7] The symptoms of FMS can be pro-
longed and debilitating. It negatively affects the lives of
patients, the people around them and the environment in
which they live. It is one of the rheumatic illnesses with
the greatest impact on patient quality of life, having nega-
tive consequences on physical capability, intellectual
activity, emotional condition, personal relationships, pro-
fessional career and mental health, to the extent where the
patient requires multiple intervention strategies. [8,9] In
recent years, FM has acquired greater significance and has
become a first-order public health problem due to preva-
lence, insufficient knowledge of its cause and the mecha-
nisms that produce it, and dissatisfaction of patients and
professionals with current therapeutic approaches.
Over 50% of the patients with FMS complain of memory
decline and mental confusion [10]. Cognitive problems,
such as forgetfulness and concentration difficulties, are
among the more severe symptoms of patients with this
condition [11]. Results from neuropsychological tests
show that patients with FMS have impairments in work-
ing, episodic and semantic memory, as well as in selective
attention [12]. Despite the importance of the cognitive
symptoms and the experts' recommendation to evaluate
them as part of the standard FMS assessment,[5] informa-
tion on the frequency of cognitive problems is limited to
a few studies as reviewed by Glass [12]. These studies used
either subjective complaints or the more complicated and
less clinically feasible of neuropsychological test evalua-
tions.
The objective of this post-hoc exploratory analysis was to
evaluate the frequency of cognitive impairment in
patients with FMS using a brief and widely used quantita-
tive measure of the cognitive status in adults such as the
Mini Mental State Examination.
Methods
Study population and overall design
The original sample was comprised of 1,519 patients of
both gender, aged ≥ 18 years, enrolled into an open label,
pragmatic, prospective, multicenter study conducted in
specialized pain care clinics (pain clinics, departments of
neurology, rheumatology clinics and department of reha-
bilitation) throughout Spain between 2002 and 2003
[13]. This study assessed the effectiveness of gabapentin
for neuropathic pain (NeP) and mixed pain (MP) of
broad origin. The eligibility criteria included: patients of
both gender aged ≥ 18 years with a clinical diagnosis of
neuropathic or mixed pain. Patients with known hyper-
sensitivity to gabapentin or its ingredients, pregnant or
nursing women, and patients receiving other analgesic
drugs indicated for neuropathic pain were excluded from
the evaluation. Patients were consecutively enrolled by
non-probabilistic sampling. Geographic representative-
ness was achieved by an unbiased selection of the special-
ized care centers throughout the whole country, and a
random enrollment of investigators in each selected
center. Thus, centre participation was proportional to the
density of the Spanish population.
From the original sample, we selected for this analysis of
the baseline data all patients with a diagnosis of FMS
according to ACR criteria as well as two age (± 1 year) and
sex-matched controls per diagnosis of NeP or MP.
The study source of data was conducted in compliance
with Spanish legal regulations for observational, post-
marketing studies of drugs. The study was reviewed and
approved by a Clinical Research Ethics Committee and
conducted in compliance with the Declaration of Hel-
sinki. A written informed consent was obtained from
patients before study entry.
Description of scales
Cognitive function was measured by administering the
Spanish version of the Mini-Mental State Examination
(MMSE), which has been validated and adjusted by age
and schooling time [14]. In this study, a score of 26 or less
was considered as any degree of cognitive impairment
(CI)[14]. Pain was assessed with the short form of the
McGill Pain Questionnaire (SF-MPQ) [15] Symptoms of
anxiety and depression were assessed by means of the
Covi [16] and Raskin [17] scales, respectively. These scales
were used in the analysis for possible confounding factors
adjustment.
Statistical methods
We conducted a post-hoc statistical analysis of data.
Crude scores of the MMSE were corrected by age and years
of schooling [14]. A descriptive analysis was performed,
including central tendency and dispersion statistics, or
ratios for categorical variables, and normal distribution
testing using the Kolmogorov-Smirnov test. A homogene-
ity analysis among three different patient groups was also
performed. This analysis used parametric and robust
(Welch and Brown-Forsythe robust tests) analysis of vari-
ance (ANOVA), depending on the variable type and distri-
bution. Categorical variables were compared using a Chi-
square test with the Yates correction, and the Fisher's exact
test in case of small sample sizes. The linear Chi-square
test was used to compare ordered ordinal variables. All
tests were two-sided, and an error of α < 0.05 was accepted
as significant.
Crude scoring in MMSE which already is corrected by age
and schooling time was adjusted for confounders byBMC Musculoskeletal Disorders 2009, 10:162 http://www.biomedcentral.com/1471-2474/10/162
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means of a multivariate lineal regression model. Con-
founders included in the model were symptoms of anxiety
and depression, last week average intensity of pain, sex
and previous exposition (before entering the study) to any
analgesic drugs or treatment for pain (i.e.: antiepileptics,
tricyclics, NSAIDs, etc.). Adjusted scoring was then used to
classify subjects as having CI (adjusted MMSE ≤ 26) and
their 95% confidence intervals calculated from the values
predicted by the regression analysis. The adjusted CI prev-
alence was compared in the different subgroups assessed
by a Chi2 test and adjusted scoring by ANOVA.
SPSS version 17.0 for Windows was used as the Statistical
package.
Results
Patients included in our analysis were mostly middle-aged
women who were less than two years after the diagnosis
of their condition. Although there were no statistically sig-
nificant differences, less than one third of FMS patients
had received previous analgesic treatment as compared
with two thirds of patients with NeP or MP. Patients in the
three study groups had moderate to severe pain as judged
by the pain score in the VAS of the SF-MPQ. Patients with
FMS exhibited significantly higher levels of anxiety and
depressive symptoms compared with the other two study
groups (Table 1).
Patients with FMS had a slight but statistically significant
lower score in the adjusted MMSE score (mean 26.9; 95%
CI: 26.7-27.1) than either patients with NeP (27.3; 27.2-
27.4) or MP (27.3; 27.2-27.5). In fact, although there were
no statistically significant differences among the study
groups in the proportion of patients with congnitive
impairment (i.e. MMSE <26), this frequency was numeri-
cally higher in patients with FMS (15%; 95% CI 6.3-29)
than in patients with NeP (5%; 95% CI 1.8-12.2) or MP
(5%; 95% CI 1.8-12.2). In the univariate analysis, patients
with at least moderate symptoms of anxiety or depression
(that is, those patients with scores equal or greater than 9
in the COVI or RASKIN, respectively) had higher rates of
cognitive impairment. However, these rates were not sig-
nificantly different among study groups (Table 2). Simi-
larly, rates of cognitive impairment did not vary according
to pain severity in any of the groups (Table 2). As
expected, the frequency of cognitive impairment appeared
to increase with age, particularly in FMS group (Figure 1).
There were no significant differences among study groups
in the rates of cognitive impaiment in each age strata.
However, a trend towards significance was found in the
group of patients 45 to 54 years old (Figure 1).
Discussion
Our results on this post-hoc analysis showed that patients
with FMS were associated with a high frequency of cogni-
tive impairment (15%, 95% CI 6.3-29), which was sub-
stantially above the known prevalence of cognitive
impairment reported for the Spanish general population
within the same age stratum (i.e. 0.05%)[18]. Rates of
cognitive impairment were not different among the study
groups according to age, pain severity or the presence of
anxiety or depressive symptoms. Noteworthy, however, is
that regardless of the diagnosis, all patients with cognitive
impairment also exhibited significant symptoms of anxi-
ety and depression (i.e. a score equal or greater than 9 in
the COVI and RASKIN scales, respectively). Despite our
Table 1: Demographic characteristics and baseline scoring in the short-form McGill Pain Questionnaire of patients with neuropathic 
pain or neuropathic and nociceptive mixed pain observed in the study.
Variable FMS
(n = 46)
NeP
(n = 92)
MP
(n = 92)
p
Age (years) 50.8 (47.8-53.8) 50.9 (48.8-53.0) 50.7 (48.6-52.8) 0.989 (F = 0.01; df = 229)
Sex, female (%) 85 [71 - 94] 85 [76 - 91] 85 [76 - 91] 1.000 (X2 = 0.002; df = 2)
Time since diagnosis (years) 1.8 (1.3-2.3) 1.4 (0.7-2.1) 1.9 (1.2-2.6) 0.434 (F = 0.69; df = 229)
0 - 12 months (%) 52 [37 - 67] 75 [65 - 83] 61 [50 - 71] 0
12 - 24 months (%) 15 [6 - 29] 10 [5 - 18] 11 [5 - 19] 0
> 24 months (%) 33 [20 - 48] 15 [9 - 24] 28 [19 - 39] 0
Previous analgesic treatment (%) 30 [187-46] 65 [59-79] 67 [57-77] 0.001 (X2 = 19.68; df = 2)
Pain score (McGill)
VAS (0 to 100): 70.8 (66.2-75.4) 71.7 (67.5-75.9) 72.6 (69.1-70.1) 0.849 (F = 0.16; df = 229)
PPI (0 to 5): 2.6 (2.3-2.9) 2.7 (2.5-3.0) 2.9 (2.7-3.0) 0.294 (F = 1.23; df = 229)
Self-perceived symptoms of;
Anxiety (COVI; 0-15) 7.0 (6.2-7.9) 5.8 (5.2-6.4) 5.8 (5.2-6.3) 0.028 (F = 3.65; df = 229)
Depression (RASKIN; 0-15) 8.4 (7.4-9.4) 6.4 (5.7-7.1) 6.5 (5.9-7.1) 0.001 (F = 7.39; df = 229)
FMS = Fibromyalgia Syndrome; NeP = Neurophatic Pain; MP = Mixed Pain; VAS = Visual Analogue Scale; PPI = Present Pain Intensity. Values are 
given as observed frequency, proportion, or mean (standard deviation) [95% confidence interval]. Except where noted, all differences are non-
significant. F = F statistic (ANOVA); df = degree of freedom. X2 = Chi2 test.BMC Musculoskeletal Disorders 2009, 10:162 http://www.biomedcentral.com/1471-2474/10/162
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cross-sectional design, this finding strongly suggests that
the cognitive impairment we observed in all these painful
conditions may be associated with underlying psycholog-
ical symptoms. Results from previous studies support this
view. Although Park et al did not find a correlation
between the impairment of cognitive performance and
depressive or anxiety symptoms in patients with FMS [19],
other authors have found an association between cogni-
tive impairment and anxiety symptoms [20] or depressive
symptoms [21,22]. Landrø et al found that only the sub-
group of patients with FMS and a lifetime history of major
depression showed memory impairment when compared
with healthy controls [21]. Suhr showed that depression
was significantly related to memory performance in
patients with FMS or other pain chronic disorders such as
chronic headache or osteoarthritis [22]. Whether the cog-
nitive impairment in FMS patients is more severe or fre-
quent than in patients with neuropathic pain or mixed
pain requires still more research as numerically differ-
ences observed in this study did not reach statistical signif-
icance due to the small sample of the study.
Our analysis has several limitations. Besides its small sam-
ple size, only a low proportion of patients with FMS (3%)
were among the patients originally recruited. This may be
due the type of participating specialist and/or because
consider this condition as a form of neuropathic pain is
still controversial. Another possible limitation is the het-
erogeneous nature of this condition; suggesting that
patients with FMS from our study could not be well clas-
sified to some extent.
Conclusion
To conclude, patients with FMS showed a high frequency
of cognitive impairment, particularly when compared
with known prevalence of this condition in the general
population. This cognitive impairment remained higher
after adjustment by the presence of anxiety and depressive
symptoms. Further studies with larger samples of patients
are required to confirm our results, to support possible
differences in frequency as compared with other painful
conditions than FMS, as well as to evaluate the potential
impact of this mild impairment of the cognitive function
on the patient's daily functionality and/or on the risk of
progression to a more severe deterioration.
Abbreviations
FMS: Fibromyalgia syndrome, NeP: Neuropathic pain,
MP: Mixed pain, MMSE: Mini-Mental State Examination,
CI: Cognitive impairment, SF-MPQ: Short Form of the
McGill Pain Questionnaire, ANOVA: Analysis of variance.
Table 2: Cognitive deficit in Fibromyalgia patients compared with subjects with neuropathic pain or mixed pain. Comparisons are 
overall, by level of symptoms of anxiety and depression, and by severity of present pain.
FMS
(n = 46)
NeP
(n = 92)
MP
(n = 92)
P
MMSE scoring
(Range 0-30); mean (95% CI)
26.9 (26.7-27.1) 27.3 (27.2-27.4) 27.3 (27.2-27.5) 0.001 (F = 7.32; df = 229)
% patients with cognitive deficit
(MMSE < 26); n, (%) [95% CI]
7 (15%) [6.3-29] 5 (5%) [1.8-12.2] 5 (5%) [1.8-12.2] 0.076 (X2 = 5.146; df = 2)
% patients with cognitive deficit by
Presence of symptoms of
Anxiety (COVI ≥ 9) 7/14 (50%) [23-77] 5/17 (29%) [10.3-56] 5/15 (33%) [11.8-61.6] 0.467 (X2 = 1.522; df = 2)
Depression (RASKIN ≥ 9) 7/19 (37%) [16.3-61.6] 5/20 (25%) [8.6-49.1] 5/21 (24%) [8.2-47.2] 0.607 (X2 = 0.999; df = 2)
Intensity of pain (average last week)
Mild (< 40) 1/2 (50%) [12.6-98.7] 1/7 (14%) [0.4-57.9] 0-3 (0%) [0-70.8] 0.328 (X2 = 2.229; df = 2)
Moderate (≥40<70) 2/15 (13%) [1.6-40.5] 2/26 (8%) [0.9-25.1] 1/26 (4%) [0-19.6] 0.537 (X2 = 1.243; df = 2)
Severe (≥ 70) 4/29 (14%) [3.9-31.7] 2/59 (3%) [0.4-11.7] 4/63 (6%) [1.8-15.5] 0.177 (X2 = 3.464; df = 2)
FMS = Fibromyalgia Syndrome; NeP = Neurophatic Pain; MP = Mixed Pain; MMSE scoring adjusted by age, sex and schooling. Cognitive deficit: 
MMSE ≤ 26 pts after adjusting by age, sex, schooling, present intensity of pain (PPI item) and severity of symptoms of anxiety (COVI) and depression 
(RASKIN). CI = Confidence interval; F = F statistic (ANOVA); df = degree of freedom. X2 = Chi2 test.
Frequency of cognitive impairment according to age and  study group Figure 1
Frequency of cognitive impairment according to age 
and study group. FMS = Fibromyalgia Syndrome; NeP = 
Neurophatic Pain; MP = Mixed Pain. Bars are mean percent-
age with upper limit 95% CI.
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